Select Equity Group’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-4,418
Closed -$717K 182
2022
Q2
$717K Sell
4,418
-936,086
-100% -$148M ﹤0.01% 145
2022
Q1
$177M Sell
940,504
-19,166
-2% -$3.64M 0.57% 48
2021
Q4
$254M Sell
959,670
-326,126
-25% -$87.9M 0.69% 45
2021
Q3
$372M Sell
1,285,796
-9,217
-0.7% -$2.36M 1.25% 29
2021
Q2
$259M Buy
1,295,013
+43,409
+3% +$8.42M 0.88% 40
2021
Q1
$243M Buy
1,251,604
+13,120
+1% +$2.69M 0.88% 34
2020
Q4
$237M Sell
1,238,484
-7,470
-0.6% -$1.36M 0.97% 33
2020
Q3
$184M Buy
1,245,954
+207,717
+20% +$29.7M 0.9% 34
2020
Q2
$128M Buy
1,038,237
+551,220
+113% +$64.8M 0.74% 36
2020
Q1
$47M Buy
+487,017
New +$47M 0.32% 63

Other funds holding RGEN

Select Equity Group's RGEN Position: Q3 2022 in Review

Select Equity Group sold out of Repligen (RGEN) in Q3 2022, closing a stake of 4,418 shares — an estimated $717K sold.

Select Equity Group first reported a position in RGEN in Q1 2020 and held it in 10 quarters. The position peaked at $372M in Q3 2021. 433 funds tracked by Wall St. Rank hold RGEN as of Q3 2022.

  • Select Equity Group reported no remaining Repligen position as of Q3 2022 after selling out during the quarter.
  • Select Equity Group sold 4,418 Repligen shares in Q3 2022, an estimated $717K.
  • Select Equity Group first reported a position in Repligen in Q1 2020 and held it in 10 quarters.
  • Select Equity Group's Repligen position peaked at $372M in Q3 2021.
  • 433 funds tracked by Wall St. Rank held Repligen as of Q3 2022.

Based on Select Equity Group's 13F filing for Q3 2022, filed 14 Nov 2022.